Quinolone resistance in Gram-negative bacilli is primarily related to mutations in the chromosomal genes encoding for type II topoisomerases, the target site of quinolones ([@B09]). However, in 1998, the first plasmid-mediated quinolone resistance (PMQR) determinant, *qnrA*, was reported in a *Klebsiella pneumoniae* strain. Since then, four additional *qnr* determinants, *qnrB*, *qnrC*, *qnrD* and *qnrS*, have been identified in Enterobacteriaceae species and some of these determinants have several allelic variants ([@B14]). These determinants encode for a pentapeptide repeat protein that binds to DNA gyrase, protecting the DNA gyrase from quinolone-mediated inhibition and increasing the minimum inhibitory concentrations (MICs) of the quinolones by eight-64-fold ([@B14]).

In addition to the *qnr* genes, various new PMQR genes have been discovered during the past decade, including the modified acetyltransferase *aac(6\')-Ib-cr* and the efflux pumps *qepA* and *oqxAB* ([@B14]).

The association of PMQR genes with extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases is note worthy ([@B02]). Although a few studies describing PMQR determinants in selected isolates have been performed, these associations have not been previously studied in Argentina ([@B13], [@B11], [@B01]). This study aimed to investigate the prevalence of PMQR genes (*qnrA*, -*B*, -*S*, -*C* and -*D*, *aac(6)-Ib-cr* and *qepA*) in oxyiminocephalosporin-resistant Enterobacteriaceae recovered during a recent multicentre survey conducted in Argentina ([@B15]). In addition, we also examined the coexistence of these determinants with different ESBL and/or AmpC β-lactamases.

The surveillance study was performed during October 2010 in 15 community hospitals distributed in three different regions of Argentina. Samples from both inpatients and outpatients were included. From 1,586 consecutive and non-repetitive enterobacterial clinical isolates recovered during this period, 207 (13.05%) displayed reduced susceptibility to expanded-spectrum cephalosporins (ESC) ([@B15]). Antimicrobial susceptibility tests were performed by dilution and diffusion methods according to the Clinical and Laboratory Standards Institute (CLSI) for ampicillin, amoxicillin - clavulanic acid, piperacillin/tazobactam, cephalothin, cefoxitin, cefotaxime, ceftazidime, cefotaxime/clavulanic acid, ceftazidime/clavulanic acid, cefepime, imipenem, meropenem, amikacin, gentamicin, tobramycin, nalidixic acid, ciprofloxacin, levofloxacin and gatifloxacin (CLSI/NCCLS 2010). Molecular epidemiology of PMQR determinants was conducted for all confirmed ESC-resistant isolates (n = 55) collected during the first week of the study (22 *K. pneumoniae*, 16 *Escherichia coli*, 6 *Proteus mirabilis*, 4 *Klebsiella oxytoca*, 3 *Serratia* spp, 3 *Enterobacter* spp and 1 *Providencia* sp.) ([@B15]). This sample was considered to be representative of the entire study period because the relative frequency of the most prevalent species was similar throughout the study period.

Molecular detection of *qnrA*, *qnrB, qnrC*, *qnrD* and *qnrS* was carried out by polymerase chain reaction (PCR) amplification using total heat-extracted DNA as a template and primers previously described ([@B03], [@B04], [@B18]). For further characterisation of *qnrB* alleles, the following primers were designed (5\'-3\'): QnrBcF: GTTRGCGAAAAAATTRACAG, QnrBlF: ATGWYGYCATTATGTATA and QnrBcR: CCMATHAYMGCGATRCCAAG. All *qnrB* amplicons were sequenced on both strands using an ABI PRISM 3700 DNA sequencer. Screening for the *aac(6\')-Ib* gene was performed using the following primers (5\'-3\'): aac(6\')IbF: CGATCTCATATCGTCGAGTG and aac(6\')IbR: TTAGGCATCACTGCGTGTTC. Characterisation of the *aac(6\')-Ib-cr* variant was conducted by restriction fragment length polymorfism-PCR using *Bse*GI (Fermentas, Thermo Fisher Scientific Inc, Massachusetts, USA) ([@B12]) and sequencing. The presence of the *qepA* gene was investigated by PCR amplification using the following primers (5\'-3\'): qepAF: ACATCTACGGCTTCTTCGTCG and qepAR: AACGCTTGAGCCCGTAGATC.

The 55 ESC-resistant isolates investigated in this study included 50 ESBL producers and the remaining five isolates were strong producers of AmpC. Among the ESBL-positive isolates, 47 were CTX-M producers (94%), with the most prevalent enzymes produced being CTX-M-2 (44%) and CTX-M-15 (38%) and to a lesser extent CTXM-14 (3/50), PER-2 (3/50), SHV-12 (2/50), SHV-5 (2/50), CTX-M-8 (1/50) and CTX-M-56 (1/50). Three isolates encoded two different ESBLs simultaneously. Susceptibility to nalidixic acid and ciprofloxacin was 7.3% and the susceptibility rate of isolates to either levofloxacin or gatifloxacin was 23.6%. Gentamicin, amikacin and tobramycin displayed susceptibility rates of 43.6%, 61.8% and 23.6%, respectively. The MIC~50~ and MIC~90~ values of the fluoroquinolones were higher for PMQR-positive *K. pneumoniae* isolates (data not shown). However, no differences in MIC values were observed within *E. coli* isolates.

High diversity of PMQR genes was found among these enterobacteria. Sixty-six percent (33/50) of ESBL-producing isolates had at least one PMQR determinant ([Table](#t01){ref-type="table"}). In contrast, no PMQR genes were detected in isolates that produced high levels of AmpC (2 *E. coli* and 1 *P. mirabilis* harbouring CMY-2 and 2 *Enterobacter* spp).

TABLEMain features of the plasmid-mediated quinolone resistance-harbouring enterobacteria isolated in this studySpeciesIsolateCityHospital*qnrB-like* allele*aac(6')-Ib* / *aac(6')-Ib-cr*ESBL genesPhylogenetic group/cloneSTMIC (µg/mL)NALCIPLEVGATGENTOBAMK*Klebisella pneumoniae*CM4CABH6*qnrB2*-/+*bla* ~CTX-M-15~NC/Kp1ST11\> 512\> 6432163244CL4CABH1*qnrB2*-/+*bla* ~CTX-M-15~NC/Kp1ST11\> 512\> 64\> 6464\> 64164I3SFH5*-*-/+*bla* ~CTX-M-15~NC/Kp1ST11\> 512\> 641616\> 64324I4SFH5*-*-/+*bla* ~CTX-M-15~NC/Kp1ST11\> 512\> 64161664164CL6CABH1*qnrB2*-/+*bla* ~CTX-M-15~NC/Kp2ST11\> 512\> 641681164CL9CABH1*qnrB1*-/+*bla* ~CTX-M-15~NC/Kp3ST486441232162T8CHH10*-*-/+*bla* ~CTX-M-15~NC/Kp4ST11\> 51264321664324CV1CABH7*qnrB19*+/+*bla* ~CTX-M-15~/ *bla* ~CTX-M-2~NC/Kp5ST11\> 512\> 646432\> 646432L5CABH3*qnrB19*-/-*bla* ~CTX-M-15~NC/NDST392\> 512\> 64442168B4CABH4*qnrB2*-/-*bla* ~CTX-M-15~NC/NDST11\> 51264\> 64640.511CV2CABH7*-*-/+*bla* ~CTX-M-2~NC/NDST15\> 5126484\< 0.544CM1CABH6*qnrB19*-/+*bla* ~CTX-M-2~NC/NDST11\> 512\> 646432\> 64\> 64\> 256B5CABH4*qnrB19*-/-*bla* ~CTX-M-2~NC/NDST11\> 512646464\> 64\> 64\> 256CL7CABH1*-*-/+*bla* ~CTX-M-2~NC/NDST11\> 512\> 641616188M2CABH7*qnrB19*-/-*bla* ~CTX-M-2~NC/NDST11\> 512\> 64\> 6464216\> 256CL5CABH1*-*-/+*bla* ~CTX-M-8~NC/NDST14648241168*Escherichia coli*L4CABH3*-*-/+*bla* ~CTX-M-15~B2/EC1aST131\> 512\> 6416161168T1CHH10*-*-/+*bla* ~CTX-M-15~B2/EC1aST131\> 512\> 646416\> 64\> 6416CM2CABH6*-*-/+*bla* ~CTX-M-15~B2/EC1bST131\> 512\> 6488\> 64328T3CHH10*-*-/+*bla* ~CTX-M-15~B2/EC1bST131\> 51264328112SM5BAH2*-*-/+*bla* ~CTX-M-15~B2/EC1cST131512210.52164M1CABH7*-*-/+*bla* ~CTX-M-15~A/EC2ST410\> 512\> 643216\> 646432SM4BAH2*-*-/+*bla* ~CTX-M-15~A/EC3ST167\> 512\> 64643221616T2CHH10*qnrB6*-/+*bla* ~CTX-M-2~B1/EC4ST297\> 512\> 64\> 64\> 642324SM7BAH2*qnrB2*-/+*bla* ~CTX-M-14~D/EC5ST68\> 512\> 64\> 6432114SM8BAH2*qnrB2*-/-*bla* ~CTX-M-14~D/EC5ST68\> 512\> 646432\< 0.50.50,5*Klebsiella oxytoca*C1SFH9*-*-/+*bla* ~CTX-M-2~NC/NDND1282428162T4CHH10*qnrB10*-/-*bla* ~CTX-M-2~NC/NDND\> 512643216\> 64\> 6416*Proteus mirabilis*SM6BAH2*qnrB2*-/-*bla* ~CTX-M-2~NC/NDND\> 512\> 64\> 64643284CX2BAH8*qnrB10*-/-*bla* ~CTX-M-2~NC/NDND12824281632T12CHH10*qnrB19*-/-*bla* ~CTX-M-2~NC/NDND\> 5123283264324*Providencia* sp.CL2CABH1*qnrB2*-/-*bla* ~CTX-M-2~NC/NDND\> 512\> 64\> 64\> 64\> 64641*Enterobacter* *cloacae*CX1BAH8*qnrB10*-/-*bla* ~PER-2~/ *bla* ~SHV-12~NC/NDND1282428164[^1]

Among the PMQR-positive isolates, 42.4% (14/33) and 33.3% (11/33) encoded either *aac(6\')-Ib-cr* or *qnrB* as a determinant of quinolone resistance respectively, while 24.3% (8/33) had both determinants. No isolates rendered a positive amplification of *qnrA*, *qnrS*, *qnrC*, *qnrD* or *qepA*.

Five *qnrB* variants were found in this study; *qnrB2-like* was the most prevalent (8/19), followed by *qnrB19-like* (6/19), *qnrB10-like* (3/19), *qnrB1-like* (1/19) and *qnrB6-like* (1/19). A homogeneous distribution of *qnrB* variants among CTX-M producers was observed ([Table](#t01){ref-type="table"}).

The *aac(6\')-Ib-cr* gene was detected in 44% (22/50) of the ESBL-producing isolates, displaying similar percentages for both *E. coli* (56.2%, 9/16) and *K. pneumoniae* (54.5%, 12/22). However, *aac(6\')-Ib-cr* was mainly associated with CTX-M-15-producing Enterobacteriaceae (15/19) and to a lesser extent with other CTX-Ms, including CTX-M-2 (5), CTX-M-15/CTX-M-2 (1), CTX-M-14 (1) and CTX-M-8 (1). One of these 22 *aac(6\')-Ib-cr*-harbouring isolates (*K. pneumoniae* CV1) also carried the wild-type *aac(6\')-Ib* gene coupled to *qnrB19* and both CTX-M-2 and CTX-M-15.

We focused on the relationship between the isolates that harboured both the *aac(6\')-Ib-cr* and *bla~CTX-M-15~* determinants. Different clones were observed among the *E. coli* (7) and *K. pneumoniae* (8) isolates ([Table](#t01){ref-type="table"}). Phylogenetic analysis ([@B05]) grouped the *E. coli* isolates into groups A (2) and B2 (5). Isolates belonging to the phylogenetic group B2 displayed a similar banding profile by REP-PCR and were characterised as ST131 according to the MLST Database (mlst.ucc.ie/mlst/dbs/Ecoli), corresponding with the worldwide pandemic clone known to cause nosocomial and community-acquired infections. Additionally, four/eight *K. pneumoniae* isolates were grouped into the same cluster (Kp1) and two of these isolates also possessed the *qnrB2* allele. According to MLST analysis ([@B08]), seven/eight *K. pneumoniae* isolates were typed as ST11 ([Table](#t01){ref-type="table"}).

The true prevalence of PMQR genes is underestimated because there are no reliable phenotypic methods to detect their presence; however, previous surveillance reports have shown the prevalence of PMQR determinants among ESBL producers ([@B07], [@B17]). Reports on contemporary isolates in Latin American countries displayed conflicting results. Nevertheless, comparisons between these studies should be performed carefully due to the different bacterial selection criteria used. In concordance with a multicentre study performed in Mexico ([@B16]), we observed a high frequency of *qnrB* and *aac(6\')-Ib-cr* genes amongst ESBL-producing isolates. However, a very low proportion of these markers were detected in Enterobacteriaceae isolated in a paediatric hospital in Uruguay ([@B10]). Furthermore, these PMQR genes have also been detected in clinical enterobacteria, with unusual phenotypes of quinolone susceptibility collected in Argentina. Compared to this study, another study reported a different distribution in the *qnrB* allelic variants and the presence of different determinants ([@B01]).

The present study highlights a putative association between *aac(6\')-Ib-cr* and *bla~CTX-M-15~* and a more homogenous distribution of *qnrB* alleles among ESBL-producing *E. coli* and *K. pneumoniae*.

Notably, some PMQR determinants have been described in multiresistant clones with worldwide distribution ([@B19]), such as *E. coli* ST131 and *K. pneumoniae* ST11, which were also detected in the present study, further underscoring the ability of these resistance mechanisms to disseminate.

In conclusion, this study is the first report the prevalence of PMQR genes in ESBL-producing Enterobacteriaceae in Argentina and suggests that the *qnrB* and *aac(6\')-Ib-cr* genes are widely dispersed among Ente-robacteriaceae, as found in many other countries. These isolates showed high-level quinolone resistance ESC resistance that was mediated by ESBLs; therefore, this study demonstrates the importance of understanding the potential risk associated with empirical treatment using these antibiotic families.

Positive controls were kindly ceded by Dr Nordman (qnrA, B and S), Dr Wang (qnrC) and Dr Kunikazu Yamane \[qepA y aac(6\')-Ib-cr\].

[^1]: AMK: amikacin; BA: Buenos Aires; CAB: Ciudad Autónoma de Buenos Aires; CH: Chubut; CIP: ciprofloxacin; ESBL: extended-spectrum β-lactamases; GAT: gatifloxacin; GEN: gentamicin; H1: Hospital de Clínicas, Universidad de Buenos Aires; H2: Corporación médica San Martín; H3: Hospital Alemán; H4: Hospital Británico; H5: Hospital Iturraspe; H6: CEMIC; H7: Sanatorio Mater Dei; H8: Hospital Eva Perón; H9: Hospital Cullen; H10: Hospital de Trelew; LEV: levofloxacin; MIC: minimum inhibitory concentration; NAL: nalidixic acid; NC: not correspond; ND: not determined; SF: Santa Fe; TOB: tobramycin.
